2025-12-25 - Analysis Report
Here's a breakdown of Merck & Co Inc (MRK) based on the provided data, encompassing simple reporting followed by analysis:

**1) Return Rate Comparison:**

*   **Ticker:** MRK
*   **Company:** Merck & Co Inc
*   **Overview:** A leading global pharmaceutical company focused on innovative medicines and vaccines.
*   **MRK Cumulative Return:** 20.29%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:**
    *   Current: -80.6
    *   Min: -104.3
    *   Max: 23.9
    *   Relative Divergence: 18.5

**Analysis:**  MRK has significantly underperformed the S&P 500 (VOO) over the period analyzed. The divergence of -80.6 indicates a substantial gap in cumulative returns. The relative divergence of 18.5 suggests the current underperformance is closer to the historical minimum divergence than the maximum, implying there may be more room for further underperformance based on the historical range.

**Alpha, Beta, CAGR, MDD Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | 1.0%   | 68.5% | -28.0%  | 0.0    | 141.2  |
| 2016-2018  | 36.0%  | 69.8% | 21.0%   | -0.0   | 191.8  |
| 2017-2019  | 40.0%  | 69.8% | 18.0%   | 0.3    | 228.3  |
| 2018-2020  | 16.0%  | 79.6% | -8.0%   | 0.3    | 205.3  |
| 2019-2021  | 2.0%   | 79.6% | -44.0%  | 0.7    | 201.6  |
| 2020-2022  | 15.0%  | 79.6% | 16.0%   | 0.7    | 291.8  |
| 2021-2023  | 33.0%  | 79.6% | 31.0%   | 0.3    | 286.8  |
| 2022-2024  | -4.0%  | 79.6% | -25.0%  | 0.2    | 261.6  |
| 2023-2025  | -29.0% | 71.5% | -94.0%  | 1.8    | 265.9  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Shows fluctuating growth, with strong periods (e.g., 2017-2019) and recent declines (2022-2025).
*   **MDD (Maximum Drawdown):** Consistently high MDD values indicate significant potential losses during the analyzed periods.
*   **Alpha:**  Alpha is the excess return of an investment relative to the return of a benchmark index. The stock is currently heavily underperforming.
*   **Beta:**  The Beta value shows increasing volatility.
*   **Cap(B):** The stock's capitalization has been relatively steady in recent years.

**2) Recent Stock Price Fluctuations:**

*   **Close (Current):** 101.09
*   **Last Market:**
    *   Price: 106.45
    *   Previous Close: 105.04
    *   Change: 1.34
*   **5-day SMA:** 99.898
*   **20-day SMA:** 100.5595
*   **60-day SMA:** 91.8107

**Analysis:** The recent price is above both the 5-day and 20-day Simple Moving Averages (SMAs), suggesting a short-term upward trend. Furthermore, the price is significantly higher than the 60-day SMA, further indicating a strong uptrend. The "Last Market" data shows a positive change, reinforcing the bullish momentum.

**3) Indicators:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment)
*   **RSI (Relative Strength Index):** 50.55 (Neutral - neither overbought nor oversold)
*   **PPO (Percentage Price Oscillator):** -0.4883 (Slightly bearish - short-term MA below long-term MA)
*   **Hybrid Signal:** Buy 100% of cash (10 shares - Very Safe - MRI:0.90), Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** 1.3 (+) (Short-term increase)
*   **Expected Return:** -47.6% (Negative - expected to underperform the S&P 500 over 2 years)

**Analysis:** The MRI suggests a "Medium Investment" recommendation. While the RSI is neutral, the PPO leans slightly bearish. The hybrid signal is bullish based on risk assessment. The recent divergence change indicates a short-term upward movement. The very negative expected return, however, is a major red flag, suggesting significant potential underperformance compared to the broader market in the long term.

**4) Recent News & Significant Events:**

*   **Positive Headlines:**  Multiple headlines highlight MRK hitting a 52-week high, a BMO upgrade, and a price surge.
*   **Mixed Headlines:** Some articles question the legitimacy of the recent run and analyze if the stock is a buy despite struggles.
*   **Dividend Increase:**  News of a dividend increase could attract income-seeking investors.

**Analysis:** The recent news is largely positive, focusing on price increases and analyst upgrades. This positive sentiment could be contributing to the recent upward price movement. However, the cautionary articles suggest the need for due diligence and raise questions about the long-term sustainability of the rally.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.90 (~Buy)
*   **Opinions:** 26
*   **Target Price:** 110.04 (Avg) / 139.00 (High) / 83.00 (Low)
*   **Recent Rating Changes:**  No specific changes provided.

**Analysis:**  Analysts generally have a positive outlook on MRK, with a consensus "Buy" rating and a mean rating close to "Buy."  The average target price of $110.04 suggests potential upside from the current price. The wide range between high and low target prices ($83 to $139) indicates some uncertainty among analysts.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-05 | 2.32  | 17.28 B$   |
| 2025-08-05 | 1.76  | 15.81 B$   |
| 2025-05-02 | 2.01  | 15.53 B$   |
| 2024-11-06 | 1.25  | 16.66 B$   |
| 2025-11-05 | 1.25  | 16.66 B$   |

**Analysis:**  Earnings per share (EPS) and revenue have shown a general upward trend over the recent quarters, with a significant jump in EPS for the most recent quarter.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.28B    | 77.69%        |
| 2025-06-30   | $15.81B    | 77.50%        |
| 2025-03-31   | $15.53B    | 77.98%        |
| 2024-12-31   | $15.62B    | 75.50%        |
| 2024-09-30   | $16.66B    | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $51.85B    | 11.16% |
| 2025-06-30   | $48.99B    | 9.04%  |
| 2025-03-31   | $48.34B    | 10.51% |
| 2024-12-31   | $46.31B    | 8.08%  |
| 2024-09-30   | $44.50B    | 7.09%  |

**Analysis:**  Revenue has been increasing, with a notable increase in the most recent quarter. Profit margins are consistently high, indicating strong profitability. Equity is growing, and Return on Equity (ROE) has also been increasing, indicating improving efficiency in generating profit from shareholder equity.

**7) Comprehensive Analysis (Summary):**

MRK's current situation presents a mixed picture:

*   **Negative Factors:** Significant long-term underperformance compared to the S&P 500, high historical Maximum Drawdown, and a very negative expected return over the next two years.
*   **Positive Factors:** Recent positive price momentum, positive news headlines, "Buy" analyst consensus, increasing revenue and EPS, strong profit margins, increasing equity and ROE, and a dividend increase.

**Overall, while MRK shows signs of short-term recovery and positive analyst sentiment, significant concerns exist regarding its long-term performance potential and risk profile.** The substantial negative expected return warrants careful consideration and further due diligence. The stock seems to be experiencing a rally driven by recent news, but fundamental challenges may persist. Investors should carefully weigh the risks and potential rewards before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.